Serum‐soluble tumor necrosis factor receptor 2 (sTNF‐R2) level determines clinical outcome in patients with aggressive non‐Hodgkin's lymphoma
- 19 July 2006
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 77 (3), 217-225
- https://doi.org/10.1111/j.1600-0609.2006.00702.x
Abstract
Background: Recently investigators have worked to identify prognostic factors in non‐Hodgkin's lymphoma (NHL) so an appropriate therapeutic plan can be put in action. The aim of the present study was to assess the prognostic significance of serum soluble tumor necrosis factor receptor (sTNF‐R) 2 in aggressive NHL. Methods: One hundred and ten consecutive patients with aggressive NHL who were previously untreated (diffuse large B‐cell lymphoma; 94, peripheral T‐cell lymphoma; 16) were prospectively enrolled in this study between 1997 and 2002. The patients were treated with 6–8 cycles of CHOP or THP‐COP regimens. Results: High serum sTNF‐Rs level was associated with some poor prognostic factors and low complete remission rate. Patients with high sTNF‐R1 (4 ng/mL and over) and sTNF‐R2 (15 ng/mL and over) at onset had significantly lower survival rates (5 yr: 19%, 19%) than those with low sTNF‐R1 (under 4 ng/mL) and sTNF‐R2 (under 15 ng/mL) (62% and 69%), respectively (P < 0.0005 and 0.0001). Multivariate analysis employing sTNF‐R2 and some conventional prognostic factors demonstrated that a combination of sTNF‐R2 and performance status, and that of sTNF‐R2, sIL‐2R, and LDH were significant prognostic factors for poor overall survival and for poor event‐free survival, respectively. In addition, we attempted to use sTNF‐R2 in combination with the international prognostic index (IPI). The patients in the high risk group and those with high sTNF‐R2 in the low‐intermediate (LI)/high‐intermediate (HI) risk group had significantly lower survival rates than the patients in the low risk group and those with low sTNF‐R2 in LI/HI risk group (P < 0.0001). Conclusions: The results suggest that a high serum sTNF‐R2 level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment when used in combination with the IPI.Keywords
This publication has 32 references indexed in Scilit:
- Distinct Differences between TNF Receptor 1- and TNF Receptor 2- mediated Activation of NFκBBMB Reports, 2005
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- The potential biological and clinical significance of the soluble tumor necrosis factor receptorsCytokine & Growth Factor Reviews, 1996
- ELEVATED CIRCULATING LEVELS OF TNFα AND ITS p55 SOLUBLE RECEPTOR ARE ASSOCIATED WITH AN ADVERSE PROGNOSIS IN LYMPHOMA PATIENTSBritish Journal of Haematology, 1996
- Lymphotoxin acts as an autocrine growth factor for Epstein‐Barr virus‐transformed B cells and differentiated Burkitt lymphoma cell linesEuropean Journal of Immunology, 1994
- Prospects for pirarubicinMedical and Pediatric Oncology, 1994
- The Pathophysiology of Tumor Necrosis FactorsAnnual Review of Immunology, 1992
- Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.The Journal of Experimental Medicine, 1992
- SERUM TUMOR NECROSIS FACTOR ALPHA ASSOCIATED WITH ACUTE GRAFT-VERSUS-HOST DISEASE IN HUMANSTransplantation, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958